July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Correlation of an Objective Fluorescein Angiography Inflammatory Scoring System with Visual and Anatomical Outcomes in Eyes with Non-Infectious Uveitis treated with Intravenous Tocilizumab
Author Affiliations & Notes
  • Mohammad Ali Sadiq
    University of Louisville, Louisville, Kentucky, United States
  • Muhammad Hassan
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Rubbia Afridi
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Muhammad Halim
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Sean Christopher Baluyot
    Ocular Imaging Research and Reading Center, Palo Alto, California, United States
  • Mohamed A Ibrahim
    Ocular Imaging Research and Reading Center, Palo Alto, California, United States
  • Diana V Do
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • yasir sepah
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Quan Dong Nguyen
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Footnotes
    Commercial Relationships   Mohammad Sadiq, None; Muhammad Hassan, None; Rubbia Afridi, None; Muhammad Halim, None; Sean Baluyot, None; Mohamed Ibrahim, None; Diana Do, None; yasir sepah, None; Quan Nguyen, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3517. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mohammad Ali Sadiq, Muhammad Hassan, Rubbia Afridi, Muhammad Halim, Sean Christopher Baluyot, Mohamed A Ibrahim, Diana V Do, yasir sepah, Quan Dong Nguyen; Correlation of an Objective Fluorescein Angiography Inflammatory Scoring System with Visual and Anatomical Outcomes in Eyes with Non-Infectious Uveitis treated with Intravenous Tocilizumab. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3517. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the correlation of an objective fluorescein angiography inflammatory scoring system with visual and anatomical outcomes in eyes with non-infectious intermediate, posterior or panuveitis being treated with intravenous infusions of tocilizumab.

Methods : STOP-Uveitis is a randomized, multi-center clinical trial that evaluated the role of tocilizumab (TCZ) in patients with non-infectious uveitis (NIU). 37 patients with NIU were randomized into one of two treatment groups to receive intravenous (IV) infusions of either 4mg/kg TCZ or 8mg/kg TCZ. Infusions were given every 4 weeks in both groups until month 6 (primary endpoint). Posterior segment inflammatory outcomes were assessed by evaluating fluorescein angiograms (FA) at baseline and month 6 visits. All images were graded by certified graders at a central reading center. A semi-quantitative, scoring system for FA was used to assess signs that represent ongoing inflammatory processes in the posterior segment. Changes in FA outcomes from baseline to month 6 were correlated with changes in central retinal thickness (CRT, as assessed by SD-OCT) and best corrected visual acuity (BCVA) during the study. Pearson correlation was used to assess the correlation between the different study parameters.

Results : 37 eyes (37 patients) were randomized in the STOP-Uveitis study. Mean change in BCVA, FA inflammatory score and CRT at month 6 have been reported in the Table. There was only a weak correlation between the FA inflammatory score and BCVA (r = 0.24), and CRT (r = 0.38) during the study. The correlation between CRT and BCVA was found to be comparatively higher (r = 0.60). No differences were observed between the two study groups.

Conclusions : TCZ (both 4 and 8 mg/kg) is effective in improving posterior segment inflammation, BCVA and CRT in eyes with non-infectious intermediate, posterior and pan-uveitis. However, improvement in the inflammatory score is not strongly correlated with improvement in vision or reduction in central retinal thickness in these eyes during the initial 6 months of therapy.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Table – Change in visual, anatomical and inflammatory markers at Month 6.

Table – Change in visual, anatomical and inflammatory markers at Month 6.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×